Proposal for the development of biologics in pediatric rheumatology. Issue 2 (22nd February 2018)

• Record Type: Journal Article
• Authors: Mori, Masaaki; Nakagawa, Masao; Tsuchida, Nao; Kawada, Kou; Sato, Junko; Sakiyama, Michiyo; Hirano, Shinya; Sato, Katsuaki; Nakamura, Hidefumi
• Is Part Of: Pediatrics international. Volume 60:Issue 2(2018)
• Page Start: 108
• Page End: 114
• Publication Date: 2018-02-22
• Subjects: biologic -- centralization -- international cooperation -- pediatric rheumatology -- registry; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/ped.13495
• Languages: English
• ISSNs: 1328-8067

Abstract

Abstract: In order to assess the development, approval and early introduction into clinical practice of biologics in the pediatric field, we herein describe the current status of the development to approval of biologics as anti‐rheumatic agents for children in Japan, discuss the present problems and provide a proposal for the future. It has become apparent that the duration of the review period required for the preparation of clinical trials and Pharmaceuticals and Medical Devices Agency approval is clearly reduced compared with the past. Thus, it was speculated that a rate‐limiting step in the process from development to approval was the duration of clinical trials from start to end. Hence, we focused on the following key words with regard to promotion of the development of biologics and their early practical use: "registry", "centralization", and "global cooperation", all of which are related to the reduction of duration of a clinical trial. In conclusion, to reduce the duration of a clinical trial, it is essential to complete a world‐scale registry system by developing the registry system established by the Pediatric Rheumatology Association of Japan. The next step is then to carefully plan to participate in the international network using the world‐scale registry system, and develop global cooperative trials in which we can ensure a sufficient number of entries from Japan.